Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000723591> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W2000723591 endingPage "279" @default.
- W2000723591 startingPage "275" @default.
- W2000723591 abstract "Objective Injectable osteoporosis drugs are increasing in popularity due to their efficacy and convenient administration. In this retrospective comparison of the two available treatments, denosumab (Prolia®) and zoledronic acid (ZA, Reclast®), we aimed to determine and compare the efficacy and tolerability of denosumab and ZA. Methods The charts of patients who received denosumab and ZA at Loyola Hospital were reviewed, and adverse events were noted. Of primary interest were myalgias, flu-like symptoms, back pain, and fractures. A questionnaire regarding the efficacy, tolerability, and treatment cost supplemented this chart review in a subset of study participants. Bone mineral density (BMD) changes, bone turnover markers, and questionnaire results were also compared. Results The study cohort consisted of 107 patients (51 denosumab, 56 ZA). The denosumab group had a greater mean increase in spine BMD at 1 year (0.060 g/cm2) than the ZA group (0.021 g/cm2; P = .04). The change in femur and spine BMD at 1 year were not significantly different between the 2 groups. The ZA group had a significantly greater incidence of mild flu-like symptoms (29% ZA group vs. 0% denosumab group; P = .04). Conclusion The denosumab group had a higher mean increase in spine BMD, and the ZA group had a higher incidence of flu-like symptoms, but the study groups were statistically similar in terms of patient satisfaction. As denosumab is still a relatively new therapy, there were a limited number of patients with posttreatment data available for comparison. As more posttherapy data become available, it can be further investigated. (Endocr Pract. 2015;21:275-279)" @default.
- W2000723591 created "2016-06-24" @default.
- W2000723591 creator A5058740477 @default.
- W2000723591 creator A5074672231 @default.
- W2000723591 creator A5084595979 @default.
- W2000723591 date "2015-03-01" @default.
- W2000723591 modified "2023-09-27" @default.
- W2000723591 title "Comparison Of The Efficacy, Adverse Effects, And Cost Of Zoledronic Acid And Denosumab In The Treatment Of Osteoporosis" @default.
- W2000723591 cites W1993035292 @default.
- W2000723591 cites W2057461358 @default.
- W2000723591 cites W2098143381 @default.
- W2000723591 cites W2158097928 @default.
- W2000723591 cites W2160005424 @default.
- W2000723591 doi "https://doi.org/10.4158/ep14106.or" @default.
- W2000723591 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25370317" @default.
- W2000723591 hasPublicationYear "2015" @default.
- W2000723591 type Work @default.
- W2000723591 sameAs 2000723591 @default.
- W2000723591 citedByCount "17" @default.
- W2000723591 countsByYear W20007235912015 @default.
- W2000723591 countsByYear W20007235912016 @default.
- W2000723591 countsByYear W20007235912017 @default.
- W2000723591 countsByYear W20007235912018 @default.
- W2000723591 countsByYear W20007235912019 @default.
- W2000723591 countsByYear W20007235912020 @default.
- W2000723591 countsByYear W20007235912021 @default.
- W2000723591 countsByYear W20007235912022 @default.
- W2000723591 countsByYear W20007235912023 @default.
- W2000723591 crossrefType "journal-article" @default.
- W2000723591 hasAuthorship W2000723591A5058740477 @default.
- W2000723591 hasAuthorship W2000723591A5074672231 @default.
- W2000723591 hasAuthorship W2000723591A5084595979 @default.
- W2000723591 hasConcept C120665830 @default.
- W2000723591 hasConcept C121332964 @default.
- W2000723591 hasConcept C126322002 @default.
- W2000723591 hasConcept C167135981 @default.
- W2000723591 hasConcept C197934379 @default.
- W2000723591 hasConcept C2776286101 @default.
- W2000723591 hasConcept C2776326535 @default.
- W2000723591 hasConcept C2776541429 @default.
- W2000723591 hasConcept C2776886416 @default.
- W2000723591 hasConcept C2778375690 @default.
- W2000723591 hasConcept C61511704 @default.
- W2000723591 hasConcept C71924100 @default.
- W2000723591 hasConceptScore W2000723591C120665830 @default.
- W2000723591 hasConceptScore W2000723591C121332964 @default.
- W2000723591 hasConceptScore W2000723591C126322002 @default.
- W2000723591 hasConceptScore W2000723591C167135981 @default.
- W2000723591 hasConceptScore W2000723591C197934379 @default.
- W2000723591 hasConceptScore W2000723591C2776286101 @default.
- W2000723591 hasConceptScore W2000723591C2776326535 @default.
- W2000723591 hasConceptScore W2000723591C2776541429 @default.
- W2000723591 hasConceptScore W2000723591C2776886416 @default.
- W2000723591 hasConceptScore W2000723591C2778375690 @default.
- W2000723591 hasConceptScore W2000723591C61511704 @default.
- W2000723591 hasConceptScore W2000723591C71924100 @default.
- W2000723591 hasIssue "3" @default.
- W2000723591 hasLocation W20007235911 @default.
- W2000723591 hasOpenAccess W2000723591 @default.
- W2000723591 hasPrimaryLocation W20007235911 @default.
- W2000723591 hasRelatedWork W1909034630 @default.
- W2000723591 hasRelatedWork W2032912145 @default.
- W2000723591 hasRelatedWork W2052478621 @default.
- W2000723591 hasRelatedWork W2362701657 @default.
- W2000723591 hasRelatedWork W2391833315 @default.
- W2000723591 hasRelatedWork W2420443437 @default.
- W2000723591 hasRelatedWork W2761771618 @default.
- W2000723591 hasRelatedWork W3032818692 @default.
- W2000723591 hasRelatedWork W4200030408 @default.
- W2000723591 hasRelatedWork W4251028680 @default.
- W2000723591 hasVolume "21" @default.
- W2000723591 isParatext "false" @default.
- W2000723591 isRetracted "false" @default.
- W2000723591 magId "2000723591" @default.
- W2000723591 workType "article" @default.